[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,033,028
  • Shares Outstanding, K 776,163
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,080 M
  • EBIT $ -1,028 M
  • EBITDA $ -1,094 M
  • 60-Month Beta -1.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 24.38

Options Overview Details

View History
  • Implied Volatility 149.81% (+12.19%)
  • Historical Volatility 113.41%
  • IV Percentile 97%
  • IV Rank 73.41%
  • IV High 183.25% on 01/27/26
  • IV Low 57.51% on 01/21/26
  • Expected Move (DTE 5) 1.39 (7.71%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 12,188
  • Volume Avg (30-Day) 10,958
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 157,147
  • Open Int (30-Day) 101,202
  • Expected Range 16.69 to 19.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 3
  • High Estimate $-0.26
  • Low Estimate $-0.26
  • Prior Year $-0.76
  • Growth Rate Est. (year over year) +65.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.14 +19.42%
on 05/01/26
29.23 -38.15%
on 04/21/26
-0.73 (-3.88%)
since 04/08/26
3-Month
14.58 +24.01%
on 02/12/26
29.23 -38.15%
on 04/21/26
+3.09 (+20.61%)
since 02/06/26
52-Week
13.83 +30.73%
on 02/05/26
30.98 -41.64%
on 08/05/25
-6.57 (-26.65%)
since 05/08/25

Most Recent Stories

More News
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference...

SMMT : 18.08 (+5.42%)
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study

SMMT : 18.08 (+5.42%)
Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members...

SMMT : 18.08 (+5.42%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 ...

SMMT : 18.08 (+5.42%)
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Conference Call to be Held at 4:30pm ET

SMMT : 18.08 (+5.42%)
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of common stock....

SMMT : 18.08 (+5.42%)
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

BLA Filing Based on HARMONi Global Phase III Study Results PDUFA Goal Action Date of November 14, 2026 Significant Unmet Need Remains;...

SMMT : 18.08 (+5.42%)
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)

Summit to Advance Development Opportunities of Ivonescimab with GSK’s Novel B7-H3 risvutatug rezetecan Multiple Solid Tumor Settings to Be Pursued with Clinical Trials...

SMMT : 18.08 (+5.42%)
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Significant Unmet Need Remains in this Setting Over 14,000 Patients are Eligible for 2L+ Treatment in This Setting in the United States Each Year ...

SMMT : 18.08 (+5.42%)
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock....

SMMT : 18.08 (+5.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 19.56
2nd Resistance Point 18.85
1st Resistance Point 18.47
Last Price 18.08
1st Support Level 17.38
2nd Support Level 16.67
3rd Support Level 16.29

See More

52-Week High 30.98
Fibonacci 61.8% 24.43
Fibonacci 50% 22.40
Fibonacci 38.2% 20.38
Last Price 18.08
52-Week Low 13.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.